Developing and Validating an In Silico Model for Proarrhythmia Risk Assessment Under the CiPA Initiative
|
|
- Herbert Wilkinson
- 5 years ago
- Views:
Transcription
1 Developing and Validating an In Silico Model for Proarrhythmia Risk Assessment Under the CiPA Initiative May 2018 Zhihua Li, PhD for the CiPA In Silico Working Group US Food and Drug Administration This presentation reflects the views of the author and should not be construed to represent FDA s views or policies
2 Comprehensive in vitro Proarrhythmia Assay (CiPA) I Ks and I Na Peak in specific situations Torsade Metric Score Check for unanticipated human effects, confirm mixed channel effects Can be considered for unanticipated nonclinical effects, or if human ECG data is insufficient
3 Model Development and Validation Strategy Select a Base Cardiomyocyte Model CiPA Training Drugs (12) Model Optimization Model Training Metric Development Evaluate the Training Results; Freeze Model for Validation CiPA Validation Drugs (16) Predict Validation Drugs Compare Prediction Accuracy to Predefined Performance Measures Model Validation
4 Model Development and Validation Strategy Select a Base Cardiomyocyte Model CiPA Training Drugs (12) Model Optimization Metric Development Model Training Evaluate the Training Results; Freeze Model for Validation Predict Validation Drugs CiPA Validation Drugs (16) Compare Prediction Accuracy to Predefined Performance Measures Model Validation 4
5 Improving the ORd Model for CiPA Modeling dynamic drug-herg interactions rather than using simple IC50s to distinguish drugs with similar herg block potency but different TdP liabilities Li Z et al. Circulation: Arrhythmia & Electrophysiology. 2017;10:e Optimizing model parameters so that the model can better recapitulate experimental data on human ventricular myocytes Dutta et al. Frontiers in Physiology. 2017;8:616 5
6 Model Development and Validation Strategy Select a Base Cardiomyocyte Model CiPA Training Drugs (12) Model Optimization Model Training Metric Development Evaluate the Training Results; Freeze Model for Validation CiPA Validation Drugs (16) Predict Validation Drugs Compare Prediction Accuracy to Predefined Performance Measures Model Validation 6
7 Key Mechanism of TdP: imbalance of Inward and Outward Currents Early after depolarization (EAD) plateau Action potential Torsade de pointes ECG Increased ratio between inward and outward currents QT Major currents modulating repolarization Inward Outward ICaL (L type calcium) IKr (potassium) The net current between inward and outward currents reflect their balance. INaL (late sodium) IKs (potassium) IK1 (potassium) Ito (potassium) Inet = ICaL+INaL+IKr+IKs+IK1+Ito qnet: Amount of electronic charge carried by Inet 7
8 Performance of qnet on 12 CiPA Training Compounds Arrhythmia Metric (qnet) EAD generated Low Risk Intermediate Risk High Risk Drug concentration (fold change over clinical exposure) Simulation with 2000 ms cycle length Drug separation is good along all concentrations from 1x to 25x Cmax 8
9 Uncertainty Quantification for TdP Risk Assessment under CiPA Developed a statistical method to translate each drug s experimental uncertainty into 2000 metric values, describing the probability distribution of its TdP risk Found that uncertainty is lowest when drug concentration is 1-4x Cmax 9
10 Torsade Metric Score for Manual Training Data 95%CI and median point of each drug s 2000 scores are shown as error bars High risk Intermediate risk Low risk Torsade Metric Score (qnet averaged 1-4 Cmax) herg (potassium channel) data: manual patch clamp Non-hERG (sodium and calcium channel) data: manual patch clamp 10
11 Torsade Metric Score for Hybrid Training Data 95%CI and median point of each drug s 2000 scores are shown as error bars High risk Intermediate risk Low risk Torsade Metric Score (qnet averaged 1-4 Cmax) herg (potassium channel) data: manual patch clamp Non-hERG (sodium and calcium channel) data: automated high throughput patch clamp systems 11
12 Model Development and Validation Strategy Select a Base Cardiomyocyte Model CiPA Training Drugs (12) Model Optimization Model Training Metric Development Evaluate the Training Results; Freeze Model for Validation CiPA Validation Drugs (16) Predict Validation Drugs Compare Prediction Accuracy to Predefined Performance Measures Model Validation 12
13 Evaluating and Freezing Model Prior to Validation On March 15 th 2017, FDA held a Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting on the topic of Model Informed Drug Development, where CiPA was presented as a potential new regulatory paradigm to seek external expert opinions A Validation Procedure document was vetted by CiPA In Silico Working Group and Ion Channel Working Group, and approved by Steering Committee prior to validation The published CiPAORdv1.0 model and qnet (Torsade Metric Score) metric, as well as classification thresholds, were frozen Defined two validation datasets: one manual and one hybrid, each 16 drugs Defined two types of performance measurements: ranking TdP risk without specific classification thresholds, and classifying drugs into one of the three risk categories using specific thresholds 13
14 Model Development and Validation Strategy Select a Base Cardiomyocyte Model CiPA Training Drugs (12) Model Optimization Model Training Metric Development Evaluate the Training Results; Freeze Model for Validation CiPA Validation Drugs (16) Predict Validation Drugs Compare Prediction Accuracy to Predefined Performance Measures Model Validation 14
15 Overall Performance on Validation Drugs High Intermediate Low Torsade Metric Score (qnet averaged 1-4 Cmax) 15
16 Rank Performance: AUC of ROC ROC (Receiver Operating Characteristic) : a curve of sensitivity vs 1-specificity for all possible cut-off (thresholds) of the metric Area Under the Curve (AUC) of ROC: probability of ranking a higher risk drug above a lower risk one ROC1: Low risk vs High-or-Intermediate ROC2: High vs Low-or-Intermediate 16
17 Procedure of ROC1 Analysis 16 validation drugs, each with 2000 torsade metric scores Two categories: High-or-Intermediate Risk; Low Risk Randomly take one score per drug Rank the 16 scores (red: High-or-Intermediate; blue: Low Risk) Lowest Score Highest Score Repeat 10,000 times Construct ROC curve Calculate AUC 17
18 Rank Performance using ROC1: Low vs High-or-Intermediate One of ROC Curves Analyze 10,000 ROC curves AUC (95% CI): 0.98 (0.93 1) AUC = 0.98 Excellent performance Performance Interpretation Minimally Good Excellent Measure acceptable AUC of ROC1 >~0.7 >~0.8 >~0.9 Probability of ranking an Intermediateor-High risk drug above a Low risk drug 18
19 Rank Performance using ROC2: High vs Low-or-Intermediate One of ROC Curves AUC = 0.96 Analyze 10,000 ROC curves AUC (95% CI): 0.94 ( ) Excellent performance Performance Interpretation Minimally Good Excellent Measure acceptable AUC of ROC2 Probability of ranking a High risk drug >~0.7 >~0.8 >~0.9 above an Intermediate-or- Low risk drug 19
20 Rank Performance using Pairwise Comparison This measure does not reduce three risk categories into two (so more comprehensive) 28 CiPA drugs -> 378 possible pairwise comparisons Removing within-category drug pairs Removing training-only drug pairs Resulting in 211 drug pairs for validation Use the model to predict pairwise ranking for each drug pair, comparing results to known ranking of TdP risk Correct prediction fraction among the 211 pairs indicates ranking performance across all 3 categories Repeat 10,000 times through random sampling, estimate confidence interval of the correct prediction fraction 20
21 Rank Performance using Pairwise Comparison One of the 10,000 prediction of 211 Drug Pairs Green: drug pairs whose ranking predicted correctly Red: drug pairs whose ranking predicted incorrectly Correct prediction fraction in this analysis: 0.97 After 10,000 repeats: 0.96 ( ) Excellent performance Performance Measure Pairwise comparison Interpretation Probability of correctly ranking a drug relative to CiPA reference drugs across 3 categories Minimally acceptable Good Excellent >~0.7 >~0.8 >~0.9 21
22 Ranking Performance Performance Measure Interpretation Manual Dataset Hybrid Dataset AUC of ROC1 Probability of ranking an Intermediate-or ( ) 0.98 (0.93 1) High risk drug above a Low risk drug AUC of ROC2 Probability of ranking a High risk drug above an Intermediate-or-Low drug 1 (0.92-1) 0.94 ( ) Pairwise Ranking Probability of correctly ranking a drug relative to CiPA reference drugs through 0.95 ( ) 0.96 ( ) pairwise comparison Below minimally acceptable Minimally acceptable Good Excellent For both manual and hybrid datasets, ranking performance of Torsade Metric Score all reached or are very close to excellent level. 22
23 Classification Performance: Likelihood Ratio (LR) Likelihood Ratio positive (LR+): how much more likely a higher risk drug is classified into the higher risk category compared to a lower risk drug Likelihood Ratio negative (LR-): 1/LR- indicates how much less likely a higher risk drug is classified into the lower risk category compared to a lower risk drug Likelihood Ratio was calculated for each of the two thresholds pre-determined by training data : threshold 1 separating low from the rest while threshold 2 separating high from the rest 23
24 Classification Performance : Likelihood Ratio of Threshold 1 95%CI and median point of each drug s 2000 scores are shown as error bars High-or-Intermediate Low Risk The hybrid validation dataset result is shown here as an example Torsade Metric Score (qnet averaged 1-4 Cmax) For LR analysis of Threshold 1, High and Intermediate combined as one category (red) 10,000 LR analyses are repeated by sampling Torsade Metric Score distributions 24
25 Classification Performance : Likelihood Ratio of Threshold 1 LR+ of Threshold 1 for Hybrid Dataset: 8e5 (7e5 1e6) 1/LR- of Threshold 1 for Hybrid Dataset: 5.5 (3.7-1e6) Performance Interpretation Minimally Good Excellent Measure acceptable LR+ of Threshold 1 How much more likely a High-or-Intermediate drug will be predicted as High-or-Intermediate, compared to a Low Risk drug? >~2 >~5 >~10 1/LR- of Threshold 1 How much less likely a High-or-Intermediate drug >~2 >~5 >~10 will be predicted as Low Risk, compared to a Low Risk drug? Wide confidence interval (CI) of 1/LR- due to perfect classification of some samples, leading to upper 95%CI value close to infinity. 25
26 Classification Performance : Likelihood Ratio of Threshold 2 LR+ of Threshold 2 for Hybrid Dataset : 6 (3 12) 1/LR- of Threshold 2 for Hybrid Dataset: 3.7 (3. 9e5) Performance Interpretation Minimally Good Excellent Measure acceptable LR+ of Threshold 1 How much more likely a High Risk drug will be predicted as High Risk, compared to a Low-or- Intermediate Risk drug? >~2 >~5 >~10 1/LR- of Threshold 1 How much less likely a High Risk drug will be >~2 >~5 >~10 predicted as Low-or-Intermediate, compared to a Low or-intermediate Risk drug? Wide confidence interval (CI) of 1/LR- due to perfect classification of some samples, leading to upper 95%CI value close to infinity. 26
27 Mean Classification Error High Intermediate Low Mean error across 16 drugs x 2000 samples 0.25 ( ) Torsade Metric Score (qnet averaged 1-4 Cmax) Performance Interpretation Minimally Good Excellent Measure Mean Classification Error Average error of classifying each of the 16 validation drugs into High, Intermediate, or Low risk category acceptable <~1 <~0.5 <~0.3 27
28 Classification Performance Performance Measure Interpretation Manual Dataset HybridDataset LR+ of Threshold 1 1/LR- of Threshold 1 LR+ of Threshold 2 1/LR- of Threshold 2 How much more likely a High-or-Intermediate drug will be predicted as High-or-Intermediate, compared to a Low Risk drug? How much less likely a High-or-Intermediate drug will be predicted as Low Risk, compared to a Low Risk drug? How much more likely a High Risk drug will be predicted as High Risk, compared to a Low-or-Intermediate Risk drug? How much less likely a High Risk drug will be predicted as High Risk, compared to a Low or-intermediate Risk drug? 4.5 (2.3 5) 8e5 (7e5 1e6) 8.8 (4.4 8e5) 5.5 (3.7 1e6) 12 (4.5 1e6) 6 (3 12) 9e5 (3.3 1e6) 3.7 (3 9e5) Mean Classification Error Average error of classifying each of the 16 validation drugs into 0.19 ( ) 0.25 ( ) High, Intermediate, or Low risk category Below minimally acceptable Minimally acceptable Good Excellent For classification measures, Torsade Metric Score on the manual and hybrid datasets mostly hit good to excellent performance. 28
29 Comparing to Alternative Metrics: Ranking Performance Performance measure Dataset Torsade Metric Score APD90 APD50 & diastolic Ca AUC of ROC1 Manual ( ) ( ) ( ) Hybrid ( ) ( ) ( ) AUC of ROC2 Manual (0.95-1) ( ) ( ) Hybrid ( ) ( ) ( ) Pairwise Comparison Correct Rate Manual ( ) Hybrid ( ) ( ) ( ) ( ) ( ) Below minimally acceptable Minimally acceptable Good Excellent All 28 drugs and leave-one-out cross validation were used. CiPA metric (qnet/tms) has excellent (>0.9) performance over all datasets and measures. 29
30 Comparing to Alternative Metrics: Classification Performance Performance measure LR+ of Threshold 1 1/LR- of Threshold 1 LR+ of Threshold 2 LR- of Threshold 2 Mean Classification Error Dataset Torsade Metric Score Manual 8.05 (4.03-9) Hybrid 8.05 ( e+05) Manual 14.7 (5.6 8e5) Hybrid 14.7 (6.3 8e5) Manual 7.5e+05 (8.75-1e+06) Hybrid 15 ( ) Manual 4 (3.8 1e6) Hybrid 3.8 ( ) Manual ( ) Hybrid ( ) APD ( ) 2.68 ( ) 5.3 ( ) 6.3 ( ) 15 ( ) 15 ( ) 3.8 ( ) 3.8 ( ) ( ) ( ) APD50 & diastolic Ca 4.03 ( ) 3.55 ( ) 7.4 ( ) 4.9 ( ) 17.5 ( e+05) 15 ( ) 4 (3.8 9e5) 3.8 ( ) ( ) ( ) Below minimally acceptable Minimally acceptable Good Excellent 30
31 Summary The CiPA model adopts the most stringent validation strategy for evaluating TdP risk prediction accuracy Over two validation datasets, the CiPA model/metric generally reaches pre-defined excellent ranking performance (5 times excellent and 1 time good), and generally good to excellent classification performance (5 times excellent, 3 good, and 2 minimally acceptable). The model s ability to achieve high performance levels across both datasets despite the data differences shows its flexibility and robustness in handling heterogeneous sources of data The current CiPA model/metric outperforms all alternative metrics tested Taken together, this work supports the regulatory use of the CiPA model 31
32 Updated CiPA Drugs Torsade Metric Scores and Thresholds 95%CI of each drug s 2000 scores are shown as error bars High Intermediate Low Torsade Metric Score (qnet averaged 1-4 Cmax) All 28 drugs were used to update the classification thresholds Some drugs in vitro data were updated with higher quality data to better reflect the underlying pharmacology 32
33 Acknowledgements CiPA Steering Committee Ayako Takei, Bernard Fermini, Colette Strnadova, David Strauss, Derek Leishman, Gary Gintant, Jean-Pierre Valentin, Jennifer Pierson, Kaori Shinagawa, Krishna Prasad, Kyle Kolaja, Natalia Trayanova, Norman Stockbridge, Philip Sager, Tom Colatsky, Yuko Sekino, Zhihua Li, Gary Mirams All CiPA Working groups Ion Channel working group In silico working group Cardiomyocyte working group Phase 1 ECG working group ALL contributors to CiPA (there are a lot!) Public-private partnerships: HESI, SPS, CSRC Regulatory Agencies: FDA, EMA, PMDA/NIHS, Health Canada Many pharmaceutical, CRO, and laboratory device companies Academic collaborators FDA Contributors Norman Stockbridge Christine Garnett David Strauss Zhihua Li Wendy Wu Sara Dutta Phu Tran Jiangsong Sheng Kelly Chang Kylie Beattie Xiaomei Han Bradley Ridder Min Wu Aaron Randolph Richard Gray Jose Vicente Lars Johannesen
34 Back-Up 34
35 Improving the ORd Model for CiPA Making the IKr/hERG component temperature dependent Modeling dynamic drug-herg interactions rather than using simple IC50s Optimizing model parameters based on experimentally recorded drug effects on human ventricular myocytes 35
36 Modeling Dynamic drug-herg Interactions Rather Than IC50s Drug block of ion channels is dynamic and can exhibit a marked dependence on voltage, time, pulse frequency and channel state (open, closed, inactivated) Measurements of IC50s are therefore only snapshots of the drug-channel interaction Drugs with similar IC50 values but different kinetics for channel blocking (and unblocking) may carry different levels of risk for producing TdP (dofetilide vs. cisapride) Specially designed voltage protocol and model are needed to capture dynamic drug-channel interaction 36
37 Dynamic herg Model to Capture Drug Binding Kinetics O = Open C = Closed I = Inactivated Li Z et al. Improving the In Silico Assessment of Proarrhythmia Risk by Combining herg-drug Binding Kinetics and Multichannel Pharmacology. In preparation Model can capture dynamic drug-herg interactions, especially drug being trapped within closed channel (red arrows) Different drugs have different propensity to be trapped in the closedbound state, leading to different TdP liability 37
38 Dynamic herg Protocol Recommended by Ion Channel Working Group Voltage protocol close -80 mv open 0 mv close -80 mv Modified from Milnes et al. J. Pharmacol. Toxicol. Methods herg Current (I) Fractional Block 1 II dddddddd II cccccccccccccc Fractional Block Time (s) 38
39 Block Development for Drugs with Different Binding Kinetics close -80 mv open 0 mv close -80 mv open 0 mv close -80 mv open 0 mv No block recovery during channel closing No block recovery during channel closing Dofetilide (highly trapped): Block recovery during channel closing Block recovery during channel closing Cisapride (less trapped): 39
40 Improving the ORd Model for CiPA Making the IKr/hERG component temperature dependent Modeling dynamic drug-herg interactions rather than using simple IC50s Optimizing model parameters based on experimentally recorded drug effects on human ventricular myocytes 40
41 Optimizing ORd Model Parameters Based on Human Cardiomyocyte Data Action Potential Duration (ms). Experimental data Before optimization After optimization Goal: adjust model parameters to more faithfully recapitulate experimental data Human cardiomyocyte action potential duration (APD) was recorded under L- type calcium current (ICaL) blocker (1 µm nisoldipine) The optimized model was able to reproduce the experimental data better than the original model Cycle Length (ms) Dutta S et al. Optimization of an In Silico Cardiac Cell Model for Proarrhythmia Risk Experimental data were taken from O Hara et al. PloS Computational Biology
42 qnet vs APD : A Case Study Q: Which cell is in a more dangerous status (closer to EAD generation)? APD: The cell with ranolazine (black) qnet: The cell with cisapride (grey) Applying the same pro-ead push Added 91.6% IKr conductance reduction (perturbation) Time (ms) Time (ms) qnet, but not APD, correctly predicts the distance from EAD qnet, but not APD, independently supports the rank order of the two drugs in CiPA categories 42
43 Comparing to Other Metrics New metrics APD Based metrics qnet Training Error Other metrics Drug Conc. (fold change over Cmax) qnet is the only metric with 0 training error across all concentrations Metrics based on action potential duration (APD), the cellular basis for QT interval, failed to classify all training drugs 43
44 ncorporating Experimental Uncertainty Experimental data have intrinsic (i.e. inherent randomness) and extrinsic (i.e. cell-to-cell variability) uncertainty This will lead to uncertainty in metric calculation and TdP risk assessment A method is needed to incorporate experimental uncertainty and calculate a probabilistic distribution of the metric 44
45 Find the Optimal Concentrations for CiPA Prediction Prediction error based on leave-one-out cross validation At each concentration, there are 12 errors, corresponding to 12 training drugs Black line: mean error across 12 training drugs Lowest prediction error achieved for 1-4x Cmax Conclusion: For CiPA manual training dataset, concentrations 1-4x Cmax should be used for qnet calculation and TdP risk prediction. 4545
46 Relationship Between In Vitro Data and In Silico Model Prediction The two datasets (Manual and Hybrid) were generated using very different experimental protocols and quality control procedures, leading to some in vitro data differences between them Internal investigation suggests dataset specific bias might be the cause of some mismatches between model prediction and actual CiPA risk Standardizing protocols and quality control criteria (ongoing effort) can potentially further increase model prediction accuracy. The model s ability to achieve high performance levels across both datasets despite the data differences shows its flexibility and robustness in handling heterogeneous sources of data
47 A Possible Explanation of the Outliers Manual Dataset Hybrid Dataset INaL IC50 (µm) INaL IC50 (µm) IC50 underestimated? Disopyramide Risk underestimated in Hybrid Metoprolol IC50 overestimated? Risk overestimated in Manual Systematic difference: 25 out of 28 drugs have a higher INaL IC50 in Manual than in Hybrid Dataset Manual Dataset Hybrid Dataset ICaL IC50 (nm) ICaL IC50 (nm) Domperidone IC50 overestimated? Risk overestimated in Hybrid Systematic difference: 21 out of 28 drugs have a higher ICaL IC50 in Hybrid than in Hybrid Dataset Outliers are dataset specific, and associated with systematic in vitro data bias due to different experimental conditions and quality criteria Establishing standard experimental procedures and quality criteria may further increase prediction accuracy 47
48 Classification Performance : Likelihood Ratio of Threshold 2 95%CI and median point of each drug s 2000 scores are shown as error bars High Risk Intermediate-or-Low The hybrid validation dataset result is shown here as an example Torsade Metric Score (qnet averaged 1-4 Cmax) For LR analysis of Threshold 2, Low and Intermediate combined as one category (blue) 10,000 LR analyses are repeated by sampling Torsade Metric Score distributions 48
49 Manual herg dynamic + Manual non-herg IC50s High Intermediate Low Torsade Metric Score (qnet averaged 1-4 Cmax) 49
50 HTS herg IC50 + HTS non-herg IC50s High Intermediate Low Torsade Metric Score (qnet averaged 1-4 Cmax) 50
51 Manual herg IC50 + Manual non-herg IC50s High Intermediate Low Torsade Metric Score (qnet averaged 1-4 Cmax) 51
In Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative
In Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative Gary Gintant, AbbVie for the Comprehensive in Vitro ProArrhythmia Assay Group Hot
More informationSuccesses and Evolving Challenges Posed by the Comprehensive In Vitro Proarrhythmia (CiPA) Initiative
Successes and Evolving Challenges Posed by the Comprehensive In Vitro Proarrhythmia (CiPA) Initiative Gary Gintant Dept. Integrative Pharmacology Integrated Sciences and Technology AbbVie For the CiPA
More informationBenchmarking In Silico Models and Candidate Metrics for Assessing the Risk of Torsade de Pointes
Benchmarking In Silico Models and Candidate Metrics for Assessing the Risk of Torsade de Pointes Sara Dutta Division of Applied Regulatory Science/OCP/CDER CRSC/HESI/SPS/FDA Meeting December 11, 2014 Silver
More informationTCP Transl Clin Pharmacol
TCP 2018;26(4):145-149 https://doi.org/10.12793/tcp.2018.26.4.145 Five years of the CiPA project (2013 2018) - what did we learn? Dong-Seok Yim* Department of Clinical Pharmacology and Therapeutics, Seoul
More informationBreakout #4 Phase 1 ECG:
Breakout #4 Phase 1 ECG: Potential Role of ECG under CiPA HESI CSRC CiPA Meeting Washington, DC - May 22, 2018 Jose Vicente, PhD Christine Garnett, PharmD Division of Cardiovascular and Renal Products
More informationCiPA, Pre-clinical Testing. Derek Leishman PhD DSP & ICH S7B
CiPA, Pre-clinical Testing Derek Leishman PhD DSP & ICH S7B Outline Introduction Scenarios Conclusion Expressing an opinion What is not covered? Analysis/critique of the components too little time to try
More informationNew ECG Biomarkers and their Potential Role in CiPA: Results and Implications
New ECG Biomarkers and their Potential Role in CiPA: Results and Implications HESI CSRC CiPA Meeting Washington, DC - May 21, 2018 Jose Vicente, PhD for the ECG Biomarker Working Group Division of Cardiovascular
More informationCan the Thorough QT Study Be Replaced? Norman Stockbridge Division of Cardiovascular and Renal Products FDA/CDER
Can the Thorough QT Study Be Replaced? Norman Stockbridge Division of Cardiovascular and Renal Products FDA/CDER Can the TQT study be replaced? Yes. Thank you. Any questions? Four genre of replacement
More informationhipsc Cardiomyocytes: Validation Study Results
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH OFFICE OF SCIENCE AND ENGINEERING LABORATORIES hipsc Cardiomyocytes: Validation Study Results Ksenia Blinova, PhD US Food and Drug Administration HESI-CSRC CiPA
More informationMEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities
MEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities Event Presenter Date EMA Workshop 2017 Tessa de Korte, MSc 2017, October 5 Page 1 Ncardia at a glance Foundation Ncardia
More informationEvolution of strategies to improve preclinical cardiac safety testing
OPINION Evolution of strategies to improve preclinical cardiac safety testing Gary Gintant, Philip T. Sager and Norman Stockbridge Abstract The early and efficient assessment of cardiac safety liabilities
More informationNcardia. Assessment of pro-arrhythmic effects in Pluricyte Cardiomyocytes. using the Axion BioSystems Maestro TM MEA system
Ncardia Stem cell experts Assessment of pro-arrhythmic effects in Pluricyte Cardiomyocytes using the Axion BioSystems Maestro TM MEA system Application note Version 2.0 Contents 1. Introduction 1 2. Assessment
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes. on the ACEA xcelligence RTCA CardioECR
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR Application Note Version 2.1 / March 2018 Contents 1. Introduction 1 2. Assessment of pro-arrhythmic
More informationMetrion Biosciences: the ion channel specialists
Metrion Biosciences: the ion channel specialists In depth profiling of human ipsc cardiomyocytes: From electrophysiology to phenotypic assays Saïd El-Haou, PhD 30 November 2017 www.metrionbiosciences.com
More informationIMPLEMENTATION OF NOVEL ECG BIOMARKERS
IMPLEMENTATION OF NOVEL ECG BIOMARKERS CSRC CiPA meeting May 21, 2018 Washington DC Borje Darpo, MD, PhD, FESC Chief Scientific Officer, Cardiac Safety, ERT 1 Disclosures I work as a consultant for ERT,
More informationPreparing for Changing Cardiac Safety Regulations. Joy Olbertz, PharmD, PhD
Preparing for Changing Cardiac Safety Regulations Joy Olbertz, PharmD, PhD Questions? Do I still have to assess proarrhythmic potential of my compound in a Thorough QT (TQT) study? If I have a TQT to conduct,
More informationMechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS)
Mechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS) Craig T. January, MD, PhD Division of Cardiovascular Medicine University of Wisconsin-Madison CSRC-HESI-FDA Rechanneling the Current Cardiac
More informationTdP Mechanisms and CiPA
TdP Mechanisms and CiPA Craig T. January, MD, PhD Division of Cardiovascular Medicine University of Wisconsin-Madison Cardiac Safety Research Consortium Hilton Washington DC December 6, 2016 Disclosures
More informationDrug-induced arrhythmogenesis. Prediction and Mechanisms. Blanca Rodriguez and Computational Biology Group University of Oxford
Drug-induced arrhythmogenesis. Prediction and Mechanisms Blanca Rodriguez and Computational Biology Group University of Oxford Feb 3 rd, 29 Work done by Esther Pueyo, Lucia Romero, Alberto Corrias, Martin
More informationDifferences in cardiac atrial and ventricular ion channels
Differences in cardiac atrial and ventricular ion channels Norbert Jost, PhD Department of Pharmacology & Pharmacotherapy, University of Szeged Division for Cardiovascular Pharmacology, Hungarian Academy
More informationComparison of Electrocardiographic Biomarkers for Differentiating. Drug-induced Single vs. Multiple Cardiac Ion Channel Block
Article Type: Article Comparison of Electrocardiographic Biomarkers for Differentiating Drug-induced Single vs. Multiple Cardiac Ion Channel Block Marina Brockway 1, Jay W. Mason 2,3, Brian P. Brockway
More informationComparison of Two Highly Automated ECG Algorithms for Detection of Drug-Induced Cardiac Ion Channel Block
Comparison of Two Highly Automated ECG Algorithms for Detection of Drug-Induced Cardiac Ion Channel Block Marina Brockway 1, Anthony A. Fossa 2 and Jay W. Mason 3,4 US Food and Drug Administration (FDA)
More informationCardiac Safety Assessment. In-Vitro/In-Vivo Extrapolation
Cardiac Safety Assessment In-Vitro/In-Vivo Extrapolation Drugs removed from the market for arrhythmia risk Courtesy of Dr. Norman Stockbridge Copyright 2014 Certara, L.P. All rights reserved. 2 Let s have
More informationQT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency
QT prolongation and drug-drug interactions Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency Disposition Introduction to QT prolongation Three relevant DDI scenarios Concluding
More informationAntiarrhythmic Drugs
Antiarrhythmic Drugs DR ATIF ALQUBBANY A S S I S T A N T P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y C O N S U L T A N T C A R D I O L O G Y & I N T E R V E N T I O N A L E P A C H D /
More informationEXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS
EXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS Christine Garnett, PharmD DCRP, FDA April 6, 2016 CSRC/FDA Workshop: The Proarrhythmic Assessment of New Chemical Entities Disclosures
More informationTQT studies - this is the end!
TQT studies - this is the end! Borje Darpo MD, PhD Associate Professor of Cardiology Chief Scientific Officer icardiac Technologies Yes as the only way to confidently exclude that a new drug has a clinically
More informationAssessment of Multi-Ion Channel Block in a Phase-1 Randomized Study Design: Results of the CiPA Phase 1 ECG Biomarker Validation Study
Article Type: Clinical Trial Accepted Article Assessment of Multi-Ion Channel Block in a Phase-1 Randomized Study Design: Results of the CiPA Phase 1 ECG Biomarker Validation Study Jose Vicente 1, Robbert
More informationCan non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium
BJP British Journal of Pharmacology RESEARCH PAPER British Journal of Pharmacology (2018) 175 606 617 606 Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results
More informationxcelligence System RTCA Cardio Instrument
xcelligence System Application Note No. 15 January 2013 xcelligence System RTCA Cardio Instrument Preclinical Cardiac Safety Assessment using Human ipsc Derived icell TM Cardiomyocytes Introduction Over
More informationJapanese Stem Cell Efforts
Japanese Stem Cell Efforts Yuko Sekino, Ph. D. Organizer of JiCSA Head, Division of Pharmacology, National Institute of Health Sciences (NIHS) Pharmaceutical and Medical Safety Bureau NI HS Since 1874
More informationIQ-CSRC Prospective Study - Background and Objectives
IQ-CSRC Prospective Study - Background and Objectives December 12, 2014 Borje Darpo MD, PhD icardiac Technologies Co-chair SoC, CSRC Objectives of the IQ-CSRC Prospective Study The objective of the initiative
More informationModels of Cardiac Electrophysiology:
Models of Cardiac Electrophysiology: A Useful Tool for Enhancing Experimental Research T. Alexander Quinn, PhD National Heart and Lung Institute, Imperial College London Department of Computer Science,
More informationCELLULAR NEUROPHYSIOLOGY
CELLULAR NEUROPHYSIOLOGY CONSTANCE HAMMOND 2. THE SODIUM ACTION POTENTIAL Video 2-1: Observations and hypotheses Sodium action potential 1 Observations 2 Patch clamp recording whole-cell configuration
More informationPredicting critical drug concentrations and torsadogenic risk using a multiscale exposure-response simulator
Predicting critical drug concentrations and torsadogenic risk using a multiscale exposure-response simulator Francisco Sahli Costabal a, Jiang Yao b, Anna Sher c, Ellen Kuhl a, a Department of Mechanical
More informationDrug-induced effects on the heart: insights from HPC simulations
Drug-induced effects on the heart: insights from HPC simulations Blanca Rodriguez Computational Biology Group University of Oxford July 1 st, 2009 Acknowledgements Esther Pueyo, Lucia Romero, Alberto Corrias,
More informationThis is the author s final accepted version.
Blinova, K. et al. (2017) Comprehensive translational assessment of humaninduced pluripotent stem cell derived cardiomyocytes for evaluating druginduced arrhythmias. Toxicological Sciences, 155(1), pp.
More informationBlocking the Late Sodium Current
Non-classical Targets in Antiarrhythmic Therapy Blocking the Late Sodium Current Luiz Belardinelli, MD SVP, Cardiovascular Therapeutics Gilead Sciences, CA, USA Madrid June 28, 2011 Disclosures: Full time
More informationEffects of reference compounds on impedance signals from stem cellderived human cardiomyocytes
Effects of reference compounds on impedance signals from stem cellderived human cardiomyocytes Herbert M. Himmel, Safety Pharmacology, Bayer Pharma AG, Wuppertal, Germany SPS Webinar Cardiac Safety Testing
More informationDrug-induced cardiotoxicity: screening methods, regulatory context, commercial environment. Beremans Ltd / Insight Pharma Reports April 2008
Drug-induced cardiotoxicity: screening methods, regulatory context, commercial environment. Overview Beremans Ltd / Insight Pharma Reports April 2008 This report identifies and discusses methods, products
More informationQT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services
QT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services The Evolution of ICH E14 Points to Consider Joint Health Canada/FDA Concept Paper
More informationmesc Derived Cardiomyocytes and the RTCA Cardio Instrument - The Perfect Match for Screening Cardiac Effects
mesc Derived Cardiomyocytes and the RTCA Cardio Instrument - The Perfect Match for Screening Cardiac Effects Dr. Kristina Tressat, Axiogenesis AG ELRIG Drug Discovery II 7-8 Sep 2011, Manchester Challange
More informationThe action potential and the underlying ionic currents. Norbert Jost, PhD
The action potential and the underlying ionic currents Norbert Jost, PhD The propagation of the stimulation in the heart Sinus node Left atria His Bundle Conduction velocity in m/s Time to arrive from
More informationDrugs, herg and sudden death
Cell Calcium 35 () 53 57 Drugs, herg and sudden death A.M. Brown a,b, a MetroHealth Campus, Case Western Reserve University, Cleveland, OH 8, USA b ChanTest, Inc., 656 Neo Parkway, Cleveland, OH 8, USA
More informationChapter 12: Cardiovascular Physiology System Overview
Chapter 12: Cardiovascular Physiology System Overview Components of the cardiovascular system: Heart Vascular system Blood Figure 12-1 Plasma includes water, ions, proteins, nutrients, hormones, wastes,
More informationThe QT Interval Safety Endpoint for DR- TB trials. Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology)
The QT Interval Safety Endpoint for DR- TB trials Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology) The ECG tracing Physiology of a cardiac myocyte Flow of ions (Na
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature19102 Supplementary Discussion Benzothiazepine Binding in Ca V Ab Diltiazem and other benzothiazepines inhibit Ca V 1.2 channels in a frequency-dependent manner consistent with pore block
More informationEarly drug development: assessment of proarrhythmic risk and cardiovascular safety
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016 VOL. 9, NO. 12, 1611 1618 http://dx.doi.org/10.1080/17512433.2016.1245142 REVIEW Early drug development: assessment of proarrhythmic risk and cardiovascular
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the ACEA xcelligence RTCA CardioECR Version 1.2 CONTENTS Getting started... 3 Technical support and training... 3 1. Introduction...
More informationLate Sodium Current Block for Drug-Induced Long QT Syndrome: Results From a Prospective Clinical Trial
Late Sodium Current Block for Drug-Induced Long QT Syndrome: Results From a Prospective Clinical Trial L Johannesen 1,2, J Vicente 1,3,4, JW Mason 5,6, C Erato 5, C Sanabria 5, K Waite-Labott 5, M Hong
More informationSafety Pharmacology Post Meeting Survey 2014
Q1 Please enter your personal information below. (If you want to be included in the 2014 Annual Meeting survey for a chance to win $200, this information is REQUIRED) Answered: 132 Skipped: 14 Name: Company:
More informationIndustry Experience of the Concentration-QTc Relationship in Phase 1 Studies. Corina Dota, AstraZeneca
Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies Corina Dota, AstraZeneca CSRC-2 th February 2012 ICH E14 2.2.5 Alternative Strategies to Assess QT/QTc Interval Effects Alternatives
More informationDevelopment and Use of Quantitative Adverse Outcome Pathways: Lessons Learned from Application to Cardiotoxicity
Development and Use of Quantitative Adverse Outcome Pathways: Lessons Learned from Application to Cardiotoxicity Chemicals Concentration 0.1 µm 1 µm 10 µm 100 µm Weihsueh A. Chiu, PhD Department of Veterinary
More informationEffects of ropinirole and rosiglitazone on action potential characteristics and ion currents in canine ventricular cells. by József Simkó, M.D.
SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (Ph.D.) Effects of ropinirole and rosiglitazone on action potential characteristics and ion currents in canine ventricular cells by József Simkó, M.D.
More informationThe overly-sensitive heart: sodium channel block and QRS interval prolongation
BJP British Journal of Pharmacology DOI:10.1111/j.1476-5381.2011.01433.x www.brjpharmacol.org COMMENTARYbph_1433 254..259 The overly-sensitive heart: sodium channel block and QRS interval prolongation
More informationComparison of different proarrhythmia biomarkers in isolated rabbit hearts
Comparison of different proarrhythmia biomarkers in isolated rabbit hearts Summary of PhD Thesis Szabolcs Orosz, MSc Supervisor: Attila Farkas MD, PhD 2nd Dept. of Internal Medicine and Cardiology Centre
More informationVoltage Gated Ion Channels
Voltage Gated Ion Channels The Machines That Make It Possible... Topics I Introduction Electrochemical Gradients Passive Membrane Properties Action Potential Voltage-Gated Ion Channels Ligand-Gated Ion
More informationAllosteric effects of erythromycin pretreatment on thioridazine block of herg potassium channels
British Journal of Pharmacology DOI:10.1111/bph.12575 www.brjpharmacol.org RESEARCH PAPER Allosteric effects of erythromycin pretreatment on thioridazine block of herg potassium channels Correspondence
More informationTargeting the late sodium channel: A new antiarrhythmic paradigm?
Targeting the late sodium channel: A new antiarrhythmic paradigm? Wojciech Zareba, MD, PhD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Disclosures: - Gilead Sciences:
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the Axion Maestro system
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the Axion Maestro system Version 1.0 CONTENTS Getting started... 3 Technical support and training... 3 1. Introduction... 4 2. Workflow...
More informationFull file at
MULTIPLE CHOICE. Choose the one alternative that best completes the statement or answers the question. 1) What electrical event must occur for atrial kick to occur? 1) A) Atrial repolarization B) Ventricular
More informationGuidance for Industry
Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs U.S. Department of Health and Human Services Food and Drug Administration
More informationInterpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety?
Interpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety? Hao Zhu, Ph.D. Scientific Lead, QT-IRT, FDA (Dec 10, 2010) Disclaimer: The views expressed in this talk are those of
More informationPreclinical Perspectives of QT Outlook from ICH Guidelines
Biometry in Early Clinical Research QT/QTc Interval Workshop in Heidelberg, November 17-19, 2005 Preclinical Perspectives of QT Outlook from ICH Guidelines Gerd Bode, M.D.,Ph.D. Frelance Consultant, e-mail
More informationHESI Technical Committee on Cardiovascular Safety: Advancing the clinical relevance of preclinical assessments
HESI Technical Committee on Cardiovascular Safety: Advancing the clinical relevance of preclinical assessments Brian R. Berridge, DVM, PhD, DACVP Committee Co-Chair ILSI Health and Environmental Sciences
More informationCellular Neurobiology BIPN 140 Fall 2016 Problem Set #2
Cellular Neurobiology BIPN 140 Fall 2016 Problem Set #2 1. (PeiXi) You are performing research on a novel ion channel and want to learn some of its characteristics. a) When you conducted voltage clamp
More informationThe plant alkaloid harmaline blocks the human voltage-gated sodium channel Na v 1.7 expressed in CHO cells: a study using automated patch clamp
Ernst Moritz Arndt University of Greifswald Institute of Pathophysiology The plant alkaloid harmaline blocks the human voltage-gated sodium channel Na v 1.7 expressed in CHO cells: a study using automated
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department
More informationChapter 3 subtitles Action potentials
CELLULAR NEUROPHYSIOLOGY CONSTANCE HAMMOND Chapter 3 subtitles Action potentials Introduction (3:15) This third chapter explains the calcium current triggered by the arrival of the action potential in
More informationDesign and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience
Design and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience Dr. Manfred Wargenau, Institute, Düsseldorf OVERVIEW Clinical background The ICH E14 guideline / review
More informationProarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform
TOXICOLOGICAL SCIENCES, 147(1), 2015, 286 295 doi: 10.1093/toxsci/kfv128 Advance Access Publication Date: June 27, 2015 Research Article Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem
More informationHHS Public Access Author manuscript Circ Res. Author manuscript; available in PMC 2016 June 05.
Tissue and Animal Models of Sudden Cardiac Death Karim Sallam, MD *,1,2,3, Yingxin Li, PhD *,1,2,3, Philip T. Sager, MD 1,2, Steven R. Houser, PhD 4, and Joseph C. Wu, MD, PhD 1,2,3 1 Stanford Cardiovascular
More informationSpironolactone (SP) is an aldosterone antagonist used in
Spironolactone and Its Main Metabolite, Canrenoic Acid, Block Human Ether-a-Go-Go Related Gene Channels Ricardo Caballero, BPharm, PhD*; Ignacio Moreno, BPharm*; Teresa González, BSc; Cristina Arias, BSc;
More informationSystems Biology Across Scales: A Personal View XXVII. Waves in Biology: Cardiac Arrhythmia. Sitabhra Sinha IMSc Chennai
Systems Biology Across Scales: A Personal View XXVII. Waves in Biology: Cardiac Arrhythmia Sitabhra Sinha IMSc Chennai The functional importance of biological waves Spiral Waves Cardiac Arrhythmias Arrhythmias:
More informationMathematical modeling of ischemia and infarction
Mathematical modeling of ischemia and infarction Mostly based on Cimponeriu, Starmer and Bezerianos: A theoretical analysis of acute ischemia and infarction using ECG reconstruction on a 2-D model of myocardium
More informationShock-induced termination of cardiac arrhythmias
Shock-induced termination of cardiac arrhythmias Group members: Baltazar Chavez-Diaz, Chen Jiang, Sarah Schwenck, Weide Wang, and Jinglei Zhang Cardiac arrhythmias, also known as irregular heartbeat, occur
More informationFor Discussion Purposes Only
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 Step 1 Draft 2 (July 17, 2003) Draft 3 (November 12, 2003), Draft 4 (June 10, 2004)
More informationICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS.
European Medicines Agency London, 25 May 2005 CHMP/ICH/2/04 ICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS ICH Step 4 NOTE FOR
More informationAssessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the Axion BioSystems Maestro TM MEA system
Assessment of pro-arrhythmic effects using Pluricyte Cardiomyocytes on the Axion BioSystems Maestro TM MEA system Version 1.2 CONTENTS Getting started... 3 1. Introduction... 4 2. Workflow... 5 Important
More informationElectrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes
Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes Based on Data from the Telemetric and Holter ECG Warehouse (THEW) Initiative Jean-PhiIippe Couderc, PhD Center for Quantitative
More informationShock-induced termination of cardiac arrhythmias
Shock-induced termination of cardiac arrhythmias Group members: Baltazar Chavez-Diaz, Chen Jiang, Sarah Schwenck, Weide Wang, and Jinglei Zhang Abstract: Cardiac arrhythmias occur when blood flow to the
More informationMeasuring Cardiac Activity:
icell Cardiomyocytes Application Protocol Measuring Cardiac Activity: Intracellular Calcium Flux Detection on the FLIPR Tetra System Introduction icell Cardiomyocytes are human cardiomyocytes that recapitulate
More informationSecond THEW Meeting, April 2009, White Oak Campus
Second THEW Meeting, April 2009, White Oak Campus 1 Pharmaceutical companies: Abbott, Astra-Zeneca, Inspire Pharmaceuticals, Inc. Johnson&Johnson, Pfizer, Roche, Shire Pharmaceuticals, Wyeth Research.
More informationBJP. British Journal of Pharmacology. MPaci 1,JHyttinen 1,BRodriguez 2 and S Severi 3
British Journal of Pharmacology RESEARCH PAPER Human induced pluripotent stem cell-derived versus adult cardiomyocytes: an in silico electrophysiological study on effects of ionic current block MPaci 1,JHyttinen
More informationAdvances in Safety Pharmacology: Utilizing ipsc-derived cardiomyocytes in early stage safety pharmacology investigations. Blake Anson, PhD.
Advances in Safety Pharmacology: Utilizing ipsc-derived cardiomyocytes in early stage safety pharmacology investigations Blake Anson, PhD. Presentation Outline I. Safety Pharmacology and in-vitro models
More informationMultiparametric assessment of the effects of chemotherapeutic drugs on the (electro)physiology of Pluricyte Cardiomyocytes
Multiparametric assessment of the effects of chemotherapeutic drugs on the (electro)physiology of Pluricyte Cardiomyocytes Event Presenter Date Ncardia Workshop Tessa de Korte, MSc December 1, 2017 Page
More informationDrugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification
Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Class I Na Channel Blockers Flecainide Propafenone Class III K channel Blockers Dofetilide,
More informationPHARMACOLOGY OF ARRHYTHMIAS
PHARMACOLOGY OF ARRHYTHMIAS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 27, 2012 Materials on: Exam #5 Required reading: Katzung, Chapter 14 1 CARDIAC ARRHYTHMIAS Abnormalities
More informationThe QT interval as it relates to the safety of non-cardiac drugs
European Heart Journal Supplements (2007) 9 (Supplement G), G3 G8 doi:10.1093/eurheartj/sum047 The QT interval as it relates to the safety of non-cardiac drugs Peter R. Kowey 1 * and Marek Malik 2,3 1
More informationEffects of adrenergic activation to the action potentials and ionic currents of cardiac cells. by Ferenc Ruzsnavszky MD
SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (PhD) Effects of adrenergic activation to the action potentials and ionic currents of cardiac cells by Ferenc Ruzsnavszky MD Supervisor: Prof. János
More informationRecent insights from the FDA QT-IRT on concentration-qtc analysis and requirements for TQT study ( waiver ) substitution
Recent insights from the FDA QT-IRT on concentration-qtc analysis and requirements for TQT study ( waiver ) substitution Dhananjay D. Marathe, Ph.D. QT-IRT Lead, Office of Clinical Pharmacology US FDA
More informationNeuroscience 201A Problem Set #1, 27 September 2016
Neuroscience 201A Problem Set #1, 27 September 2016 1. The figure above was obtained from a paper on calcium channels expressed by dentate granule cells. The whole-cell Ca 2+ currents in (A) were measured
More informationBIONB/BME/ECE 4910 Neuronal Simulation Assignments 1, Spring 2013
BIONB/BME/ECE 4910 Neuronal Simulation Assignments 1, Spring 2013 Tutorial Assignment Page Due Date Week 1/Assignment 1: Introduction to NIA 1 January 28 The Membrane Tutorial 9 Week 2/Assignment 2: Passive
More informationIn silico assessment of drug safety in human heart applied to late sodium current blockers
Channels ISSN: 1933-6950 (Print) 1933-6969 (Online) Journal homepage: http://www.tandfonline.com/loi/kchl20 In silico assessment of drug safety in human heart applied to late sodium current blockers Beatriz
More informationIon channel dysfunction and diseases of the heart
Basisvorlesung (BVO) Zelluläre Signaltransduktion- Krankheitsbilder Sommersemester 2015 902.384 PhD- Programm Molecular Signal Transduction Ion channel dysfunction and diseases of the heart H. Todt Dpt.
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/6/278/rs11/dc1 Supplementary Materials for In Vivo Phosphoproteomics Analysis Reveals the Cardiac Targets of β-adrenergic Receptor Signaling Alicia Lundby,* Martin
More informationIs There a Genomic Basis to Acquired Channelopathic disease
Is There a Genomic Basis to Acquired Channelopathic disease Yaniv Bar-Cohen, M.D. Associate Professor of Pediatrics Division of Cardiology / Electrophysiology Children s Hospital Los Angeles Keck School
More informationInPulse: Development of an ipsc cardiomyocyte (ipsc-cm) platform to assess drug-induced contractility liabilities.
InPulse: Development of an ipsc cardiomyocyte (ipsc-cm) platform to assess drug-induced contractility liabilities. Sponsors: Arun Sridhar, Peter J. Clements, Brian Berridge, Drug induced contractility
More informationBasics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD
Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD University of Pittsburgh Medical Center Pittsburgh, PA International Symposium of Inherited Arrhythmia Disorders and Hypertrophic
More informationChapter 3 Neurotransmitter release
NEUROPHYSIOLOGIE CELLULAIRE CONSTANCE HAMMOND Chapter 3 Neurotransmitter release In chapter 3, we proose 3 videos: Observation Calcium Channel, Ca 2+ Unitary and Total Currents Ca 2+ and Neurotransmitter
More information